RRosenblatt NNVIDIA · NVDA

Rosenblatt Reiterates Nvidia’s $245 Price Target

Dec 26, 2025· 1 min read· Reproduced verbatim
Rating
Unknown
Price target
$245
Previous
—
Upside at publication
+30%

Rosenblatt analyst Kevin Cassidy reiterated on December 26, 2025, the firm’s $245 price target on Nvidia.

“On Wednesday, December 24th, Groq announced a non-exclusive inference technology licensing agreement with NVIDIA.

NVIDIA management has not made public comments on this agreement.

Strategically we view that licensing an inference technology as important for NVIDIA.

This would address concerns around Google’s TPU taking GPU market share as AI expands into the inference stage.

Importantly, the deal includes key Groq managers, including Groq’s founder and original TPU designer, Jonathan Ross, joining NVIDIA.

An interesting angle on this deal is the potential for NVIDIA’s CUDA development tools to expand Groq’s LPU (Language Processing Unit) use across multiple end markets.

We see this transaction furthering NVIDIA’s AI market dominance.

We continue recommending NVDA shares for the company’s leadership in the AI market. Our 12-month target price is $245.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.